Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential

Francesco Menzella, Mirco Lusuardi, Carla Galeone, Sofia Taddei, Nicola Facciolongo, Luigi Zucchi

Research output: Contribution to journalReview articlepeer-review


Severe asthma is characterized by major impairment of quality of life, poor symptom control and frequent exacerbations. Inflammatory, clinical and causative factors identify different phenotypes and endotypes of asthma. In the last few years, new treatment options have allowed for targeted treatments according to the different phenotypes of the disease. To accurately select a specific treatment for each asthmatic variant, the identification of appropriate biomarkers is required. Eosinophilic asthma is a distinct phenotype characterized by thickening of the basement membrane and corticosteroid responsiveness. This review reports the latest evidence on an anti-IL-5 monoclonal antibody, mepolizumab, a new and promising biological agent recently approved by the FDA specifically for the treatment of severe eosinophilic refractory asthma.

Original languageEnglish
Pages (from-to)260-277
Number of pages18
JournalTherapeutic Advances in Chronic Disease
Issue number6
Publication statusPublished - Nov 1 2016


  • asthma
  • costs
  • effectiveness
  • IL-5
  • mepolizumab
  • phenotype

ASJC Scopus subject areas

  • Medicine (miscellaneous)


Dive into the research topics of 'Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential'. Together they form a unique fingerprint.

Cite this